Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 101

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Study on Verapamil SR for Adults with Newly Diagnosed Type 1 Diabetes to Preserve Beta-Cell Function

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Medical University Of Graz

Neoplasm+1

Not recruiting

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VERT-002
  • Sponsor:Pierre Fabre Medicament

Infertility

Not recruiting

Study on Subfertility: Comparing Estradiol Valerate and Micronised Progesterone for Frozen-Thawed Embryo Transfer in Women Seeking Pregnancy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Estradiol Valerate
  • Sponsor:UZ Leuven

Cardiac amyloidosis

Not recruiting

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study on Avacopan with Rituximab or Cyclophosphamide for Children Aged 6 to 17 with Active ANCA-associated Vasculitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avacopan
  • Sponsor:Amgen Inc.

Colon cancer

Not recruiting

Study of Dostarlimab for Patients with Untreated Stage III Resectable Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:UZ Leuven

Narcolepsy

Not recruiting

Study on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of Livmoniplimab and Budigalimab Compared to Chemotherapy for Adults with Advanced Bladder Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.